By 2030, the number of GLP-1 users in the US could reach 30 million, representing approximately 9% of the population
Platforms that blur education and sales claims face higher compliance risk
Compounded Semaglutide: A Question of Source Ideally, a compounding pharmacy could manufacture compounded semaglutide if the semaglutide source is approved for human use in the U.S
If you still don't see the email, try waiting for a few minutes
The dose escalation process unfolds over several months, with increases occurring every four weeks
And if, say, a cancer patient could demonstrate that BPC-157 use accelerated their tumor (a very difficult causal link to prove scientifically, but hypothetically), the liability could be enormous